影像引导宫颈癌三维腔内放疗的临床初步观察

doi:10.3969/j.issn.1007-3969.2015.11.011

中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (11): 906-910.doi: 10.3969/j.issn.1007-3969.2015.11.011

影像引导宫颈癌三维腔内放疗的临床初步观察

龚　唯，徐晓婷，李　莉，张汝婷，倪　婕，徐玥靓，秦颂兵，周菊英

苏州大学附属第一医院放疗科，江苏苏州 215006

出版日期:2015-11-30 发布日期:2016-02-01
通信作者: 徐晓婷　E-mail：szting110@163.com
基金资助:
国家自然科学基金(81302384)。

Clinical preliminary observation on image-guided brachytherapy for cervical cancer

GONG Wei, XU Xiaoting, LI Li, ZHANG Ruting, NI Jie, XU Yueliang, QIN Songbing, ZHOU Juying

Department of radiotherapy, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China

Published:2015-11-30 Online:2016-02-01
Contact: XU Xiaoting E-mail: szting110@163.com

摘要/Abstract

摘要： 背景与目的：放射治疗是宫颈癌的主要治疗方法。通过分析苏州大学附属第一医院放疗科收治的31例初治宫颈癌患者三维腔内放疗的剂量体积直方图(dose-volume histogram，DVH)剂量分布和临床结果，观察影像引导宫颈癌三维后装放疗患者的近期疗效及放射反应。方法：选取2013年5月—2014年12月在苏州大学附属第一医院放疗科行根治性放疗的31例初治宫颈癌患者，FIGO期为Ⅱa~Ⅳ期。每例患者接受4~6次CT引导下的三维后装放疗，单次高危临床靶区(high risk-clinical target volume，HR-CTV)给予400~600 cGy处方剂量，31例患者共计153次施源器置入，采用¹⁹²Ir高剂量率后装治疗机实施腔内放疗。分析内外照射的HRCTVD90、膀胱D2cc、乙状结肠D2cc、直肠D0.1cc和直肠D2cc，采用EQD2进行剂量计算。按照RTOG/EORTC放射反应评分标准和RECIST 1.1评价标准分析放射反应和近期疗效。结果：膀胱、直肠、乙状结肠均无3级及以上急性或慢性放射反应。2例患者发生后期直肠出血(2级)，经止血和灌肠等对症处理后症状改善。放疗后1~3个月完全缓解率(complete remission，CR)为93.55%(29/31)，1年局部控制率(local control rate，LCR)为93.55%(29/31)，1年无进展生存率(progression-free survival，PFS)为90.32%(28/31)。结论：CT引导的三维腔内放疗联合外照射治疗局部晚期宫颈癌，定位精确，靶区剂量充足，危及器官的受照剂量可见、可控、可信，提高了患者的治疗耐受性，避免了重度放射反应的发生，大大提高了患者治疗后的生活质量，值得推广应用。

关键词: 宫颈癌, 影像引导, 三维后装放疗, 近期疗效, 放射反应

Abstract: Background and purpose: The radiation therapy is the main treatment of cervical cancer. In order to investigate the efficacy and toxicity of the 3D image-guided brachytherapy for cervical cancer, we analyzed dose-volume histogram (DVH) dose distribution and clinical data from 31 cases of cervical cancer treated with three dimensional brachytherapy. Methods: From May. 2013 to Dec. 2014, 31 cervical cancer cases with FIGO stage Ⅱa-Ⅳ received comprehensive treatment in our department. High risk-clinical target volume (HR-CTV) was 400-600 cGy per fraction, and totally 4-6 fractions for each patient. A total of 152 times 3D-CT guided brachytherapy was performed with ¹⁹²Ir high-dose-rate afterloader. We calculated the doses with EQD2 and analyzed the data on HRCTV D90, bladder D2cc, sigmoid D2cc, rectum D0.1cc and rectum D2cc of both the external-beam radiotherapy and CT-guided brachytherapy. The efficacy and toxicity were evaluated by RTOG/EORTC and RECIST (version 1.1) guideline. Results: There was no third degree reaction occurring on bladder, rectum or sigmoid. Two patients developed second degree chronic rectal bleeding 3 months after the completion of radiotherapy which were well controlled by medications. The tumor complete remission rate (CR) was 93.55% (29/31) 1-3 months after the treatment. Local control rate (LCR) rate was 93.55% (29/31) one year after the treatment, whereas disease-free survival rate (DFS) was 90.32% (28/31). Conclusion: The 3D CT-guided brachytherapy combined with external radiation for locally advanced cervical cancer showed positioning accuracy with an adequate dose distribution to the target area. The treatment made the OR dose visible, controllable and credible. It improved the treatment of patients with increased tolerance and avoided the severe radiation reactions. Thus, the combination therapy may greatly improve the quality of life for patients, and ought to be promoted.

Key words: Cervical cancer, Image-guided, 3D brachytherapy, Efficacy, Toxicity

龚　唯,徐晓婷,李　莉,等. 影像引导宫颈癌三维腔内放疗的临床初步观察[J]. 中国癌症杂志, 2015, 25(11): 906-910.

GONG Wei, XU Xiaoting, LI Li, et al. Clinical preliminary observation on image-guided brachytherapy for cervical cancer[J]. China Oncology, 2015, 25(11): 906-910.

[1]	方艳惠, 马彩娟, 张纯丽, 翟嘉威, 朱巧英, 刘茵, 赵喜娃. miR-496通过SFMBT1抑制子宫颈癌HeLa细胞增殖、迁移和侵袭的相关研究[J]. 中国癌症杂志, 2021, 31(8): 697-703.
[2]	龙行涛, 周琦, 王冬, 陈月梅, 金福军 . 子宫颈癌2018年FIGO新分期ⅢC期患者预后分析[J]. 中国癌症杂志, 2021, 31(8): 725-733.
[3]	中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南（2021年版）[J]. 中国癌症杂志, 2021, 31(6): 474-489.
[4]	董诗洁, 胡晓欣, 王　葳, 杨　孟, 岳　磊, 童　彤, 顾雅佳. 基于多序列MRI与多体系影像组学模型预测子宫颈癌淋巴结转移的研究[J]. 中国癌症杂志, 2021, 31(6): 460-467.
[5]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[6]	沈　洁, 莫　淼, 袁　晶, 周昌明, 王泽洲, 张志红, 温　灏, 吴小华, 郑　莹 . 1 313例局部晚期宫颈癌患者的长期生存报告：以医院为基础的真实世界研究[J]. 中国癌症杂志, 2020, 30(3): 192-198.
[7]	陈晓慧, 王佳舟, 胡伟刚, 彭佳元, 翟　鹏. 加速器模型和治疗计划系统对知识库计划模型的影响：一项基于宫颈癌适形调强放射放疗计划的研究[J]. 中国癌症杂志, 2020, 30(10): 821-825.
[8]	王　利,任玉兰,王华英 . 宫颈癌根治术后肺栓塞1例报道[J]. 中国癌症杂志, 2019, 29(8): 599-601.
[9]	刘山，房娟，王黎黎，张映红，杜文杰，朱桃花. 宫颈癌周围神经侵犯与复发高危因素的关联研究[J]. 中国癌症杂志, 2019, 29(6): 439-444.
[10]	赵雨笛，谭芳，严志凌，李盈甫，戴书颖，周紫云，张新文，刘舒媛，史荔，姚宇峰. CD44基因多态性与宫颈癌及非小细胞肺癌的相关性[J]. 中国癌症杂志, 2019, 29(4): 277-283.
[11]	周　薇,张志将,王丽君,等. 中国子宫颈癌1987-2014年死亡趋势的Joinpoint回归分析[J]. 中国癌症杂志, 2017, 27(8): 634-640.
[12]	冯定庆,闫克芹,张筱,等. Piwil2调控宫颈癌细胞恶性生物学行为的机制探讨[J]. 中国癌症杂志, 2017, 27(12): 921-927.
[13]	段雅晨,陈小军,吴小华. HPV的外周循环血测定及临床意义[J]. 中国癌症杂志, 2017, 27(11): 908-912.
[14]	刘　健,崔艳艳,李胜泽,等. 新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析[J]. 中国癌症杂志, 2016, 26(5): 427-433.
[15]	武　丹,杨　昕,朱君玲,等. 新疆维吾尔族妇女子宫颈癌DBC1基因启动子甲基化分析[J]. 中国癌症杂志, 2016, 26(3): 208-214.

影像引导宫颈癌三维腔内放疗的临床初步观察

Clinical preliminary observation on image-guided brachytherapy for cervical cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价